Virtus ETF Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Virtus ETF Advisers’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,895	Closed	-$63.2K	–	467
2023 Q3	$63.2K	Sell	2,895 -287	-9%	-$7.18K	0.04%	398
2023 Q2	$101K	Sell	3,182 -578	-15%	-$17.7K	0.06%	375
2023 Q1	$91.7K	Sell	3,760 -1,451	-28%	-$42.6K	0.05%	356
2022 Q4	$164K	Buy	5,211 +916	+21%	+$25.8K	0.09%	328
2022 Q3	$121K	Buy	4,295 +36	+0.8%	+$1.07K	0.05%	397
2022 Q2	$113K	Sell	4,259 -957	-18%	-$27.2K	0.04%	400
2022 Q1	$183K	Sell	5,216 -309	-6%	-$9.02K	0.08%	204
2021 Q4	$179K	Sell	5,525 -10,142	-65%	-$358K	0.07%	251
2021 Q3	$462K	Sell	15,667 -817	-5%	-$22.9K	0.2%	152
2021 Q2	$422K	Buy	+16,484	New	+$236K	0.17%	188

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Virtus ETF Advisers's CERE Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 2,895 shares — an estimated $63.2K sold.

Virtus ETF Advisers first reported a position in CERE in Q2 2021 and held it in 10 quarters. The position peaked at $462K in Q3 2021. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

Virtus ETF Advisers reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Virtus ETF Advisers sold 2,895 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $63.2K.
Virtus ETF Advisers first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Virtus ETF Advisers's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $462K in Q3 2021.
195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.